Abstract:In non-small cell lung cancer (NSCLC) RAS-mutant status is a negative prognostic and predictive factor. The prevalence, clinicopathology and genetic variability of RAS mutation NSCLC patients are unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring RAS mutations. We retrospectively reviewed clinical features from 41 patients with RAS gene mutation NSCLC, and the survival rate was calculated by Kaplan-Meier method and log-rank test was used to compare the survival rates. KRAS gene mutation rate was 8.00% (38/475) in NSCLC, including G12C (9 patients), G12D (8 patients), G12V (7 patients), G12A (2 patients), G12S (2 patients), G13D (2 patients), Q61H (2 patients), G12L (1 patient), G12 (1 patient), G12K (1 patient), G12fs*3 plus G12V (1 patient), G13C plus V14I (1 patient) and K5N (1 patient). Mutation rate of current-smoker was much higher than non-smoker (15.76% and 4.41%, P<0.01), and median overall survival (OS) for these patients was 18.3 months; NRAS gene mutation rate was 0.29% (1/346), G12D, and OS for these patients was 14.2 months; HRAS gene mutation rate was 0.63% (2/315), including H27N and N85I, and median OS for both patients was 19.2 months. Among them, 18 cases of the 41 RAS mutation patients with co-occurring mutations had a median OS of 28.0 months, and median OS of the 23 patients without complex mutations was 21.0 months. No statistically significant difference was found between the two groups (P=0.06). Briefly, patients of KRAS mutations with (n=4) or without (n=34) co-occurring EGFR mutations had a median OS of 40.0 months and 16.3 months respectively (P=0.07); patients with (n=3) or without (n=35) co-occurring TP53 mutations had a median OS of 36.4 months and 18.3 months respectively (P=0.22); patients with (n=3) or without (n=35) co-occurring STK11 mutations had a median OS of not reached so far and 16.3 months respectively (P=0.22); patients with (n=2) or without (n=36) co-occurring KEAP1 mutations had a median OS of 43.6 months and 16.3 months respectively (P=0.06). Mutation rate of KRAS gene in current-smoker NSCLC patients was higher than no-smoker, there is no other significant difference of molecular features in RAS gene mutations in NSCLC. Patients with complex mutations benefited more from therapy than those with single mutations. Immunotherapy may displayed moderate efficacy in patients with TP53 and RAS co-exist mutations.

Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance

Impact Of Genetic Alterations On Outcomes Of Patients With Stage I Nonsmall Cell Lung Cancer: An Analysis Of The Cancer Genome Atlas Data

A gene expression signature predicts survival of patients with stage I non-small cell lung cancer.

Characterization of Distinct Types of KRAS Mutation and Its Impact on First-Line Platinum-Based Chemotherapy in Chinese Patients with Advanced Non-Small Cell Lung Cancer

[Study of Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer].

Prognostic factors for survival in a Chinese population presenting with advanced non-small cell lung cancer with an emphasis on smoking status: A regional, single-institution, retrospective analysis of 4552 patients

The prognostic impact of epidermal growth factor receptor mutation in clinical stage I lung adenocarcinoma

Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer.

Association of Oncogene Driver Mutations with Recurrence and Survival in Stage I Nonsmall Cell Lung Cancer

Distinct Prognostic Factors in Patients with Stage I Non–Small Cell Lung Cancer with Radiologic Part-Solid or Solid Lesions

Clinical Genetic Features and Related Survival Implications in Patients with Surgically Resected Large-Cell Lung Cancer

P1.02-047 Mutational Features and Prognosis of Non-Small-Cell Lung Cancer Harboring RAS Mutations

Distinct Clinicopathologic Factors and Prognosis Based on the Presence of Ground-Glass Opacity Components in Patients with Resected Stage I Non-Small Cell Lung Cancer

Clinicopathological Variables Influencing Overall Survival, Recurrence and Post-Recurrence Survival in Resected Stage I Non-Small-cell Lung Cancer

Prognostic Significance of Pretreatment Laboratory Parameters in Combined Small-Cell Lung Cancer

Prognostic Significance of Genotype and Number of Metastatic Sites in Advanced Non-Small-cell Lung Cancer.

[Gene mutation characteristics of clinical stage ⅠA lung adenocarcinoma and their relations with patients' long-term prognosis]

Pan-Driver-Negatives Versus Epidermal Growth Factor Receptor Mutants for C-Stage IA Lung Adenocarcinoma with Ground-Glass Opacity

Histopathologic Pattern and Molecular Risk Stratification Are Associated with Prognosis in Patients with Stage IB Lung Adenocarcinoma

Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer

Study of prognostic predictors for non-small cell lung cancer